Anzeige
Mehr »
Mittwoch, 06.08.2025 - Börsentäglich über 12.000 News

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2APCZ | ISIN: US5588681057 | Ticker-Symbol: YDO1
Tradegate
05.08.25 | 20:30
292,30 Euro
-0,07 % -0,20
Branche
Pharma
Aktienmarkt
NASDAQ Biotech
1-Jahres-Chart
MADRIGAL PHARMACEUTICALS INC Chart 1 Jahr
5-Tage-Chart
MADRIGAL PHARMACEUTICALS INC 5-Tage-Chart
RealtimeGeldBriefZeit
290,10295,1009:30
290,10295,0009:27

Aktuelle News zur MADRIGAL PHARMACEUTICALS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DiMadrigal Pharmaceuticals stock surges as Goldman reiterates buy on strong sales4
DiMadrigal jumps as MASH drug Rezdiffra drives massive Q2 beat6
DiMADRIGAL PHARMACEUTICALS, INC. - 10-Q, Quarterly Report2
DiMadrigal Pharmaceuticals, Inc. GAAP EPS of -$1.90 beats by $1.51, revenue of $212.8M beats by $50.63M11
DiMadrigal Pharmaceuticals, Inc.: Madrigal Pharmaceuticals Reports Second-Quarter 2025 Financial Results and Provides Corporate Updates119Second-quarter 2025 Rezdiffra (resmetirom) net sales of $212.8 millionAs of June 30, 2025, more than 23,000 patients on Rezdiffra Received new U.S. Rezdiffra patent providing protection to Feb. 4...
► Artikel lesen
MoMadrigal Pharmaceuticals Q2 2025 Earnings Preview7
MADRIGAL PHARMACEUTICALS Aktie jetzt für 0€ handeln
FrMadrigal Pharmaceuticals: Neue Hochs in Sicht?250Madrigal Pharmaceuticals befindet sich aktuell in einer vielversprechenden Phase: Das Unternehmen erzielt steigende Umsätze mit seinem Medikament Rezdiffra und steht vor mehreren strategischen Wachstumschancen....
► Artikel lesen
DoCSPC Pharmaceutical Secures USD2.1 Billion Global Licensing Deal with Madrigal for Oral GLP-1 Drug8
30.07.Madrigal buys into GLP-1 from CSPC; Apellis wins expanded drug approval6
30.07.Madrigal in-pact with CSPC Pharma for obesity drug license10
30.07.Madrigal pens $2B pact for CSPC's preclinical GLP-1 with eye on Rezdiffra MASH pairing2
30.07.MADRIGAL PHARMACEUTICALS, INC. - 8-K, Current Report7
30.07.Madrigal secures global license for oral GLP-1 drug to combine with Rezdiffra9
30.07.CSPC PHARMA Forges Exclusive License Deal w/Madrigal for SYH2086, Entitled to Receive Max. USD2.075B in Total7
30.07.Madrigal Pharmaceuticals, Inc.: Madrigal Pharmaceuticals Enters into Exclusive Global License Agreement for Oral GLP-1 Receptor Agonist with CSPC Pharmaceutical Group Limited729License agreement supports Madrigal's pipeline strategy to develop innovative combination treatments for MASH, anchored by its foundational therapy Rezdiffra (resmetirom) Combining Rezdiffra with...
► Artikel lesen
29.07.Gabriel Iglesias, Maria Bamford, Al Madrigal, Big Jay Oakerson, Ron Funches & More Set For Just For Laughs Toronto3
25.07.Madrigal Pharmaceuticals, Inc.: Madrigal Pharmaceuticals to Release Second-Quarter 2025 Financial Results and Host Webcast on August 5, 20257
22.07.Madrigal Pharmaceuticals secures $500M credit facility from Blue Owl12
22.07.MADRIGAL PHARMACEUTICALS, INC. - 8-K, Current Report7
22.07.Madrigal Pharmaceuticals, Inc.: Madrigal Pharmaceuticals Secures $500 Million in Senior Secured Credit from Blue Owl Managed Funds to Further Extend Leadership Position in MASH3
Weiter >>
92 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1